Antibody composition and application thereof to detection of acute B lymphocytic leukemia

An antibody composition and B cell technology, applied in the field of blood disease detection, can solve the problems of CD24 expression reduction, antigen expression loss, loss, etc., and achieve the effect of reducing the probability of missed diagnosis

Active Publication Date: 2021-03-26
信纳克(北京)生化标志物检测医学研究有限责任公司
View PDF5 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the correct selection of antibody composition is the key to achieve the above goals. For example, the most conventional analysis scheme is the membrane pan-B cell marker CD19 supplemented with SSC or CD45 (CD19/SSC or CD45/CD19 dual parameters) for gating However, for patients after CD19-CAR-T cell infusion treatment, using CD19 to set up a gate is no longer applicable, because after treatment, some normal or abnormal B cell surface CD19 antigens have shown loss of expression or weakened, so it is urgent to find a new effective solution that can set the gate to select the target B cells
[0006] In order to solve this problem, researchers have done research explorations, including the study of Washington University using CD22 combined with CD24+/CD66c- gate B cells to detect MRD

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antibody composition and application thereof to detection of acute B lymphocytic leukemia
  • Antibody composition and application thereof to detection of acute B lymphocytic leukemia
  • Antibody composition and application thereof to detection of acute B lymphocytic leukemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0061] Example 1 preparation

[0062] The combination of the antibody used in this example is,

[0063] A1 is: CD38-FITC, CD10-PE, CD34-PERCP-CY5.5, CD19-PE-CY7, CD20-APC-CY7, CD45-V500, taking the above six monoclonal antibody reagents by volume ratio 5: 5: 5: 3: 2: 3 is mixed in the first container;

[0064] A2 is: Cytoplasm CD79A-APC, mounted in a second container;

[0065] B1 is: CD81-PE, CD34-PERCP-CY5.5, CD10-PE-CY7, CD45-V500, and the above four monoclonal antibody reagents are mixed in the third container in the third container by volume ratio 5: 5: 3: 3. ;

[0066] B2 is: TDT-FITC, cytoplasmic CD79A-APC, and the above two monoclonal antibody reagents are mixed in the fourth vessel in volume ratio 2: 3. The antibodies in this embodiment are commercially available, with TDT-FITC for the United States Beckman Coulter products, cytoplasmic CD79A-APC is a four-yard company product, and the remaining fluorescein direct labeling antibody is American Bectondickinson's products.

...

Embodiment 2

[0068] Example 2 Treatment of specimens

[0069] According to the result of the cell count, heparin or EDTA anticoagulated bone marrow or peripheral blood sample is added to the flow tube tube, and the amount of cells to be added is about 2 × 10 6 Others, then in the flow tube, 23 μl of different fluorescein-labeled six cell membrane monoclonal antibody reagents were added to the flow tube, and the cell suspension was sufficiently mixed with normal temperature to incubate for 15 minutes, and 100 μl of broken membrane A liquid, EtOAc EtOAc EtOAc EtOAc EtOAc EtOAc EtOAc EtOAc EtOAc EtOAc EtOAc (EtOAc) ), At room temperature and removal for 15 minutes, and finally 3 ml of PBS buffer washing, centrifugation was removed, and the cell was resuspended with 0.5 mL of PBS buffer, which was to handle the test.

[0070] Table 1

[0071]

[0072] According to the result of the cell count, heparin or EDTA anticoagulated bone marrow or peripheral blood sample is added to the flow tube tube, a...

Embodiment 3

[0075] Example 3 Detection of specimens

[0076] The specimen will be processed according to the method of Example 2, in the US BECTON Dickinson 3 laser 8-color FACS Canto II flow cytometry, preferably obtains 1 million cells per tube (recommended at least 300,000), use Diva 2.8 Software or other software analysis data such as Kaluza.

[0077] Among them, the flow cytokines are detected in the following ways:

[0078] 1 fixed door: to remove the adhesion cell door, live cell door, blood cell door; 2 multi-marking combination door: starting from a single living cell, in order to prevent leakage tumor cells, B-based marker, unripe B The cell logo gates need to be carried out with the blood cell door under side by side; 3 In the multi-marking portfolios, common B cell development models of various marker combinations are displayed, and tumor cells are found according to the normal cells.

[0079] 1. Fixed door: from the delayed cell door, living cell door, blood cell door. In series....

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides an antibody composition and application thereof to detection of acute B lymphocytic leukemia. The antibody composition comprises four groups of antibodies; the first group of antibodies includes a CD38 antibody, an anti-CD10 antibody, an anti-CD34 antibody, an anti-CD19 antibody, an anti-CD20 antibody and an anti-CD45 antibody; the second group of antibodies includes an anti-cytoplasm CD79a antibody; the third group of antibodies includes an anti-CD81 antibody, an anti-CD34 antibody, an anti-CD10 antibody and an anti-CD45 antibody; and the fourth group of antibodies includes an anti-TdT antibody and an anti-cytoplasm CD79a antibody. The antibody composition disclosed by the invention can be applied to detecting acute B lymphocytic leukemia and/or minimal residual disease by flow cytometry, and can be used for effectively selecting B cells in a gating manner, including B cells of CD19- and B cells of CD19+, and the B cells cover the most complete immature B cell population and even B cell population, so that the missed diagnosis probability is reduced.

Description

Technical field [0001] The present invention relates to an antibody composition and its application in leukemia detecting acute B lymphocytes, belonging to the field of blood disease testing. Background technique [0002] In recent years, the incidence of leukemia / lymphoma has increased significantly, and has become one of the important diseases affecting human health. Acukaemia, ALL is 15% of all leukemia, accounting for about 30% -40 of acute leukemia. %, 80-85% of B Cell type (B-All). In the United States, the incidence of ALL is 1.38 / 100,000 per year. There are about 5930 cases of new cases per year, and 1,500 deaths. Domestic research shows that the incidence of male ALL in Shanghai from 2008 to 2012 is 0.86 / 100,000, and the incidence of female ALL is 0.76 / 100,000, and the incidence rate is 0.69 / 100,000 from 1986 to 1988. [0003] With the continuous emergence of new therapies such as targeted therapy, leukemia, lymphoma has a cure hope, and the current treatment m...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K16/28G01N15/14
CPCC07K16/2803C07K16/2887C07K16/289C07K16/2896G01N15/14
Inventor 王卉陈曼王爱先傅旻婧
Owner 信纳克(北京)生化标志物检测医学研究有限责任公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap